Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRANCIS-ACS: Varespladib Methyl in Acute Coronary Syndromes
NCT00743925Phase 2Completed
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Jul 2008
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in acute coronary syndrome (ACS) comparing Varespladib Methyl + Atorvastatin with Placebo + Atorvastatin (2 arms). Primary endpoints: Low-Density Lipoprotein Cholesterol at 8 weeks, High-Sensitivity C-Reactive Protein at 8 weeks and 1 more. Started Jul 2008; status: completed.
02
Drugs
varespladib methyl
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00743925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00743925.